Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

October 12, 2017: By Joan McKenna
Notal Vision's ForeseeHome monitoring device

Notal Vision’s ForeseeHome monitoring device

Notal Vision announced Oct. 5 that patients have used its ForeseeHome monitoring device 3 million times.

It is the first US FDA-cleared home monitoring system for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD.

The self-administered test is designed to detect wet AMD at an earlier stage, allowing doctors to treat patients sooner in disease progression and possibly prevent loss of sight.

The system received US clearance in December 2009 and was used in clinical research before being commercially launched in October 2013. It gained Medicare reimbursement in 2016.

In 2010, the National Eye Institute began using the ForeseeHome in a secondary study to AREDS2 in 1,500 patients. Ninety percent of patients who used the device twice weekly and progressed to wet AMD maintained 20/40 or better vision, compared with 62 percent of patients whose diagnosis was during a routine eye exam or visit triggered by symptoms.

Notal Vision is headquartered in Tel Aviv, Israel, with a US office and distribution center in Virginia.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility